Diffuse Large B Cell Lymphoma Pipeline Report 2021: Comprehensive Insights on 80+ Companies and Respective Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diffuse Large B Cell Lymphoma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

“Diffuse large B cell lymphoma Pipeline Insight, 2021” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Diffuse large B cell lymphoma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse large B cell lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse large B cell lymphoma.

Diffuse large B cell lymphoma Emerging Drugs Chapters

This segment of the Diffuse large B cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diffuse large B cell lymphoma Emerging Drugs

Epcoritamab: Genmab

Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ broad oncology collaboration. Currently, it is in phase 3 stage of development for the treatment of Diffuse large B cell lymphoma.

Glofitamab: Roche

Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format which we call ‘2:1’, which refers to the structure of the antibody.

It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. A robust clinical development programme for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, and other blood cancers.

Acalabrutinib: Acerta Pharma

Acalabrutinib is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.

This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

AUTO 3: Autolus

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently in phase I/II stage of development for the treatment of diffuse large B cell lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, it is in phase 2 stage of development for the treatment of Diffuse large B cell lymphoma.

Diffuse large B cell lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Diffuse large B cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diffuse large B cell lymphoma

There are approx. 80+ key companies which are developing the therapies for Diffuse large B cell lymphoma. The companies which have their Diffuse large B cell lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genmab.

Key Players

• Genmab
• Roche
• Acerta Pharma
• Autolus
• Xynomic Pharmaceuticals
• Genentech
• Celgene
• AbbVie
• Mabion
• Pharmacyclics LLC.
• Shanghai Yingli Pharmaceutical
• Philogen
• Amgen
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• JW Therapeutics
• Incyte Corporation
• BeiGene
• Miltenyi Biotec GmbH
• Beijing InnoCare Pharma Tech Co., Ltd.
• Bristol-Myers Squibb
• Celleron Therapeutics
• Otsuka Pharmaceutical
• Curis, Inc.
• Bayer
• Kartos Therapeutics, Inc.
• Shanghai Institute Of Biological Products
• Novartis Pharmaceuticals
• Constellation Pharmaceuticals
• Secura Bio, Inc.
• CytomX Therapeutics
• Juno Therapeutics
• Teneobio, Inc.
• Telios Pharma, Inc.
• Sorrento Therapeutics, Inc.
• Curocell Inc.
• TG Therapeutics, Inc.
• Tessa Therapeutics
• TCR2 Therapeutics
• Plexxikon
• Shattuck Labs, Inc.
• MEI Pharma, Inc.
• Boryung Pharmaceutical Co., Ltd
• Sutro Biopharma, Inc
• Newave Pharmaceutical Inc
• Eden BioCell Ltd.
• Adicet Bio, Inc
• VelosBio Inc.
• Seagen Inc.
• Eisai Co Ltd
• Nurix Therapeutics, Inc.
• Prelude Therapeutics
• Xencor

Key Products

• Epcoritamab
• Glofitamab
• Acalabrutinib
• AUTO 3
• Abexinostat
• Atezolizumab
• Durvalumab
• Venetoclax
• MabionCD20
• Ibrutinib
• YY-20394
• Mosunetuzumab
• L19-IL2 fusion protein
• Blinatumomab
• Anlotinib Hydrochloride
• JWCAR029
• TQ-B3525
• INCB053914
• Zanubrutinib
• MB-CART2019.1
• ICP-022
• Ipilimumab
• Nivolumab
• CXD101
• OPB-111077
• CUDC-907
• Copanlisib
• KRT-232
• SIBP-02
• VAY736
• CPI-0209
• Duvelisib
• CX-2029
• CC-97540
• TNB-486
• TL-895
• STI-3031
• Ublituximab
• CRC01
• CD30.CAR-T
• TC-110 T Cells
• PLX2853
• SL-279252
• ME-401
• BR101801
• STRO-001
• LP-168
• RPM CD19-mbIL15-CAR-T cells
• ADI-001
• VLS-101
• SEA-TGT
• Tazemetostat
• NX-2127
• PRT543
• XmAb13676

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xfm5nl

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900